08/05/2024
Read Response from Dr Elisabete Weiderpass to Professor Nelson Gouveia, President of the International Society for Environmental Epidemiology, Sao Paulo, Brazil, 5 May 2024
Read Letter from Professor Nelson Gouveia, President of the International Society for Environmental Epidemiology to Dr Elisabete Weiderpass, 30 April 2024
01/03/2018
IARC strongly rejects the premise of the article published on 28 February 2018 by Reuters (WHO cancer agency “left out key findings” in benzene review). No key findings were left out of the IARC evaluation of benzene as a cause of cancer, and IARC provided extensive responses to Dr Kopstein′s questions. The article, which severely distorts the assessment of the IARC Monographs evaluation, is the latest in a series of misleading reports by Reuters. In the best interests of global public health and transparency, IARC is posting its full response to the journalist on its website, as it has consistently done.
Read IARC rejects false claims in Reuters article: WHO cancer agency “left out key findings” in benzene review, 1 March 2018
09/02/2018
Read IARC’s comment on the outcome of the Committee on Science, Space, and Technology Hearing, 9 February 2018
02/02/2018
Read IARC response to criticisms of the Monographs and the glyphosate evaluation, January 2018
12/01/2018
On 8 December November 2017, the United States House of Representatives Committee on Science, Space, and Technology sent a new letter to Dr Christopher Wild, Director of the International Agency for Research on Cancer (IARC). In the interest of transparency, IARC is posting Dr Wild′s response to the United States House of Representatives Committee on Science, Space, and Technology, as sent today.
Read Response from Dr Wild to the Committee on Science, Space and Technology, 11 January 2018
Read Letter from the Committee on Science, Space and Technology to Dr Wild, 8 December 2017
20/11/2017
On 1 November 2017, the United States House of Representatives Committee on Science, Space, and Technology sent a letter to Dr Christopher Wild, Director of the International Agency for Research on Cancer (IARC), raising several points mentioned in some media outlets regarding the evaluation of glyphosate by the IARC Monographs Programme. IARC has issued a number of statements to reject false claims and misrepresentations in the media; these statements are all available on our website. In the interest of transparency, IARC is posting Dr Wild′s response to the United States House of Representatives Committee on Science, Space, and Technology, as sent today.
Read Response from Dr Wild to the Committee on Science, Space and Technology, 20 November 2017
Read Letter from the Committee on Science, Space and Technology to Dr Wild, 1 November 2017
Following the classification of glyphosate in March 2015 as probably carcinogenic to humans (Group 2A) by the IARC Monographs Programme, IARC has been the target of an unprecedented number of orchestrated actions by stakeholders seeking to undermine its credibility. In the interest of transparency, IARC has documented some of these instances, and our responses can be found on the Agency′s Governance website.
- IARC rejects false claims in Reuters article (“In glyphosate review, WHO cancer agency edited out “non-carcinogenic” findings”), 24 October 2017
- IARC Statement on IARC Monographs deliberations, 9 October 2017
- IARC responds to Reuters article of 14 June 2017, 16 June 2017
24/10/2017
An article published on 19 October 2017 by Reuters severely distorts the assessment of the IARC Monographs evaluation of glyphosate. IARC addresses a series of fallacious statements made in that article regarding the scientific deliberations of the Monographs Working Groups and reiterates the critical importance of a scientific debate free from vested interests, in the best interest of global public health. Read
09/10/2017
Members of the IARC Monograph Working Group which evaluated glyphosate in March 2015 have expressed concern after being approached by various parties asking them to justify scientific positions in draft documents produced during the Monographs process. IARC would like to reiterate that draft versions of the Monographs are deliberative in nature and confidential. Scientists should not feel pressured to discuss their deliberations outside this particular forum.
02/03/2016
Kathryn Guyton Scientist and Kurt Straif, Head of the Section of Evidence Synthesis and Classification, IARC
More information
Following the classification of glyphosate in March 2015 as probably carcinogenic to humans (Group 2A) by the IARC Monographs Programme, IARC has been the target of an unprecedented number of orchestrated actions by stakeholders seeking to undermine its credibility. In the interest of transparency, IARC has documented some of these instances, and our responses can be found on the Agency′s Governance website.
24/10/2017
16/06/2017
IARC responds to Reuters article of 14 June 2017
26/10/2016
IARC responds to Reuters article of 25 October 2016